Daina Graybosch
Stock Analyst at Leerink Partners
(1.32)
# 3,649
Out of 5,127 analysts
98
Total ratings
42.65%
Success rate
-6.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $1.93 | +3.63% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.78 | +12.68% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.54 | +269.34% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $2.98 | +134.90% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $15.25 | -21.31% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $117.15 | +1.58% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.03 | +297.61% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $67.23 | -41.99% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $56.00 | -19.64% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.09 | +817.43% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $20.78 | +82.87% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.74 | +68.78% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $108.93 | +105.64% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.00 | +1,400.00% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.72 | +2,268.68% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.76 | +411.36% | 4 | Feb 25, 2022 |
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $1.93
Upside: +3.63%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.78
Upside: +12.68%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.54
Upside: +269.34%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $2.98
Upside: +134.90%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $15.25
Upside: -21.31%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $117.15
Upside: +1.58%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.03
Upside: +297.61%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $67.23
Upside: -41.99%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $56.00
Upside: -19.64%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.09
Upside: +817.43%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $20.78
Upside: +82.87%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.74
Upside: +68.78%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $108.93
Upside: +105.64%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.00
Upside: +1,400.00%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.72
Upside: +2,268.68%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.76
Upside: +411.36%